Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone health after switching from TDF-based ART to Biktarvy in virologically suppressed adults with HIV
2018-004499-36Phase 4Active
- Sponsor
- Parc de Salut Mar
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Parc de Salut Mar. Primary endpoints: Bone tissue quality by microindentation and Worsening criterion for bone quality. Started Jun 2019; status: active.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2018-004499-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004499-36.